(DVA) DaVita HealthCare Partners - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 12.751m USD | Total Return: 39.8% in 12m
Avg Turnover: 161M
EPS Trend: 90.4%
Qual. Beats: 2
Rev. Trend: 99.8%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Confidence, Garp
DaVita Inc. (DVA) is a leading provider of kidney care services in the United States, specializing in dialysis treatments for patients with chronic kidney failure and End-Stage Renal Disease (ESRD). The company operates an extensive network of outpatient centers and clinical laboratories, offering hemodialysis, peritoneal dialysis, and home-based treatment options alongside hospital inpatient services.
The business model relies heavily on government reimbursement rates, as a significant portion of dialysis patients qualify for Medicare coverage due to the life-sustaining nature of the treatment. Beyond clinical operations, DaVita integrates physician services, transplant software, and risk-based care management to oversee the full continuum of kidney health. Comprehensive financial metrics and valuation models for DVA are available on ValueRay for those seeking deeper analysis. The sector is characterized by a high degree of consolidation, with DaVita and one other major competitor managing the majority of the U.S. outpatient dialysis market.
- Medicare reimbursement rate updates dictate primary revenue growth and operating margins
- Shift toward home-based dialysis modalities reduces facility overhead and labor costs
- GLP-1 drug adoption trends impact long-term patient population growth projections
- Labor market volatility and clinical staffing shortages pressure service delivery costs
- Expansion of value-based care contracts shifts financial risk from payers to provider
| Net Income: 781.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -1.75 > 1.0 |
| NWC/Revenue: 8.64% < 20% (prev 5.62%; Δ 3.01% < -1%) |
| CFO/TA 0.12 > 3% & CFO 2.03b > Net Income 781.4m |
| Net Debt (15.1b) to EBITDA (2.70b): 5.58 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.9m) vs 12m ago -15.26% < -2% |
| Gross Margin: 31.10% > 18% (prev 0.32%; Δ 3.08k% > 0.5%) |
| Asset Turnover: 79.93% > 50% (prev 75.76%; Δ 4.17% > 0%) |
| Interest Coverage Ratio: 3.54 > 6 (EBITDA TTM 2.70b / Interest Expense TTM 559.8m) |
| A: 0.07 (Total Current Assets 4.06b - Total Current Liabilities 2.87b) / Total Assets 17.5b |
| B: -0.01 (Retained Earnings -179.2m / Total Assets 17.5b) |
| C: 0.11 (EBIT TTM 1.98b / Avg Total Assets 17.3b) |
| D: -0.02 (Book Value of Equity -266.1m / Total Liabilities 16.5b) |
| Altman-Z'' = 1.17 = BB |
| DSRI: 1.01 (Receivables 2.98b/2.76b, Revenue 13.8b/13.0b) |
| GMI: 1.04 (GM 31.10% / 32.46%) |
| AQI: 0.99 (AQ_t 0.47 / AQ_t-1 0.48) |
| SGI: 1.07 (Revenue 13.8b / 13.0b) |
| TATA: -0.07 (NI 781.4m - CFO 2.03b) / TA 17.5b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 195.57 with a total of 408,815 shares traded.
Over the past week, the price has changed by -1.98%,
over one month by +30.34%,
over three months by +28.21% and
over the past year by +39.80%.
DaVita HealthCare Partners has received a consensus analysts rating of 3.10. Therefore, it is recommended to hold DVA.
- StrongBuy: 1
- Buy: 0
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 193.7 | -1% |
P/E Trailing = 19.1203
P/E Forward = 13.6986
P/S = 0.9216
P/B = 21.6266
P/EG = 0.6167
Revenue TTM = 13.8b USD
EBIT TTM = 1.98b USD
EBITDA TTM = 2.70b USD
Long Term Debt = 10.5b USD (from longTermDebt, last quarter)
Short Term Debt = 544.9m USD (from shortTermDebt, last quarter)
Debt = 15.8b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.59b
Net Debt = 15.1b USD (calculated: Debt 15.8b - CCE 748.7m)
Enterprise Value = 27.8b USD (12.8b + Debt 15.8b - CCE 748.7m)
Interest Coverage Ratio = 3.54 (Ebit TTM 1.98b / Interest Expense TTM 559.8m)
EV/FCF = 18.64x (Enterprise Value 27.8b / FCF TTM 1.49b)
FCF Yield = 5.37% (FCF TTM 1.49b / Enterprise Value 27.8b)
FCF Margin = 10.79% (FCF TTM 1.49b / Revenue TTM 13.8b)
Net Margin = 5.65% (Net Income TTM 781.4m / Revenue TTM 13.8b)
Gross Margin = 31.10% ((Revenue TTM 13.8b - Cost of Revenue TTM 9.53b) / Revenue TTM)
Gross Margin QoQ = 31.42% (prev 28.28%)
Tobins Q-Ratio = 1.59 (Enterprise Value 27.8b / Total Assets 17.5b)
Interest Expense / Debt = 3.54% (Interest Expense 559.8m / Debt 15.8b)
Taxrate = 19.40% (66.2m / 341.2m)
NOPAT = 1.60b (EBIT 1.98b * (1 - 19.40%))
Current Ratio = 1.42 (Total Current Assets 4.06b / Total Current Liabilities 2.87b)
Debt / Equity = -20.93 (negative equity) (Debt 15.8b / totalStockholderEquity, last quarter -755.5m)
Debt / EBITDA = 5.58 (Net Debt 15.1b / EBITDA 2.70b)
Debt / FCF = 10.09 (Net Debt 15.1b / FCF TTM 1.49b)
Total Stockholder Equity = 871.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.51% (Net Income 781.4m / Total Assets 17.5b)
RoE = 74.40% (Net Income TTM 781.4m / Total Stockholder Equity 1.05b)
RoCE = 17.15% (EBIT 1.98b / Capital Employed (Equity 1.05b + L.T.Debt 10.5b))
RoIC = 10.56% (NOPAT 1.60b / Invested Capital 15.1b)
WACC = 5.28% (E(12.8b)/V(28.6b) * Re(8.28%) + D(15.8b)/V(28.6b) * Rd(3.54%) * (1-Tc(0.19)))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.41 | Cagr: -12.40%
[DCF] Terminal Value 73.10% ; FCFF base≈1.60b ; Y1≈1.40b ; Y5≈1.13b
[DCF] Fair Price = 48.64 (EV 18.2b - Net Debt 15.1b = Equity 3.12b / Shares 64.2m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 90.39 | EPS CAGR: 27.32% | SUE: 1.70 | # QB: 2
Revenue Correlation: 99.76 | Revenue CAGR: 5.93% | SUE: 1.38 | # QB: 2
EPS current Quarter (2026-06-30): EPS=3.84 | Chg30d=+5.94% | Revisions=+11% | Analysts=6
EPS next Quarter (2026-09-30): EPS=3.93 | Chg30d=+3.46% | Revisions=+11% | Analysts=6
EPS current Year (2026-12-31): EPS=14.80 | Chg30d=+4.79% | Revisions=+64% | GrowthEPS=+37.3% | GrowthRev=+3.7%
EPS next Year (2027-12-31): EPS=17.18 | Chg30d=+4.78% | Revisions=+45% | GrowthEPS=+16.1% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: +64%